Table 1 Clinical, hematologic, and cytogenetic characteristics of the MDS patients
Age | Sex | Diagnosis | Screening | Karyotype [No. Metaphases with aberrration] | Clinical outcome | Total cycles | Duration of therapy (Months) | Time to first response (Cycles) | Duration of response (Months) | Survival (Months) | Time to AML Evolution (Months) | Cause of death | Clinical response’s subgroup for molecular analysis | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
WHO | WPSS | ||||||||||||||
1† | 67 | M | RAEB-2 | VERY-HIGH | 25/03/2013 | COMPLEX | SD | 10 | 10 | 14 | 8 | AML | NR | ||
2† | 67 | F | RAEB-2 | HIGH | 02/04/2013 | 46, XX | CR | 30 | 28 | 6 | 24 | 35 | 28 | OVARIAN CANCER | R |
3† | 71 | M | RAEB-2 | HIGH | 29/04/2013 | 47, XY, + 8 | mCR | 38 | 36 | 4 | 10 | 41 | 36 | AML, INFECTION | R |
4† | 76 | F | RAEB-2 | HIGH | 13/05/2013 | 46, XX | HI | 8 | 8 | 4 | 5 | 12 | 9 | AML, CACHEXIA | LR |
5† | 68 | M | RAEB-1 | HIGH | 13/05/2013 | COMPLEX | SD | 9 | 9 | 14 | PNEUMONIA, CARDIAC FAILURE | NR | |||
6† | 67 | M | RAEB-2 | HIGH | 23/05/2013 | 46, XY | PR | 10 | 10 | 2 | 6 | 30 | 10 | AML | LR |
7† | 72 | M | RAEB-1 | HIGH | 26/06/2013 | 46, XY, del (7) (q22;34) [20]; del (7q31) [18] | SD | 8 | 8 | 22 | 20 | CEREBRAL HEMORRHAGE | NR | ||
8 | 82 | M | RAEB-2 | HIGH | 28/06/2013 | 46, XY | CR | 41 | 42 | 2 | 40 | 42 | R | ||
9 | 67 | F | RAEB-1 | HIGH | 01/07/2013 | 47, XX, + 8 | HI + mCR | 12 | 18 | 2 (mCR); 5 (HI) | 8 (HI); 16 (mCR) | 42 | R | ||
10 | 73 | F | RAEB-1 | INT | 10/07/2013 | 45, X, del X, del (20q) | HI + mCR | 38 | 42 | 3 (HI); 4 (mCR) | 35 (HI); 34 (mCR) | 42 | R | ||
11† | 75 | F | RAEB-1 | HIGH | 10/07/2013 | 47, XX, + 8 | HI | 20 | 21 | 1 | 19 | 28 | 21 | DISEASE PROGRESSION | R |
12 | 76 | M | RAEB-1 | INT | 22/07/2013 | 46, XY | HI + mCR | 8 | 8 | 1 | 5 (HI); 6 (mCR) | 38 | LR | ||
13† | 70 | M | RAEB-2 | HIGH | 29/08/2013 | 46, XY | CR | 27 | 40 | 2 | 38 | 40 | R | ||
14† | 72 | F | RCMD-RS | HIGH | 09/09/2013 | COMPLEX | HI + mCR | 13 | 14 | 2 | 11 | 16 | 15 | AML, SEPSIS | LR |
15† | 68 | M | RCMD | HIGH | 03/10/2013 | 45, XY, del 7 | HI | 3 | 3 | 1 | 2 | 3 | SUDDEN DEATH | NR | |
16† | 66 | F | RAEB-2 | HIGH | 15/10/2013 | 46, XX | SD | 8 | 8 | 14 | 14 | AML | NR | ||
17† | 48 | F | RAEB-2 | VERY-HIGH | 6/11/2013 | 47, XY, + 8 | CR | 16 | 15 | 2 | 11 | 26 | DISEASE PROGRESSION | R | |
18† | 64 | F | RAEB-1 | INT | 6/11/2013 | 46, XX | HI | 10 | 10 | 5 | 3 | 12 | PULMONARY CARCINOMA | LR | |
19† | 66 | M | RAEB-2 | VERY-HIGH | 15/11/2013 | 47, XY, + 8 | HI | 9 | 9 | 3 | 5 | 10 | WORSENING OF CLINICAL CONDITIONS | LR | |
20† | 75 | F | RAEB-2 | HIGH | 22/11/2013 | 46, XX | HI | 10 | 10 | 2 | 7 | 11 | 11 | AML | LR |
21† | 83 | M | RAEB-2 | HIGH | 04/02/2014 | 47, XX, + 8 [5] | SD | 6 | 6 | 11 | 9 | AML | NR | ||
22† | 71 | F | RAEB-2 | VERY-HIGH | 17/02/2014 | COMPLEX | CR | 7 | 7 | 2 | 5 | 12 | 9 | AML, SEPSIS | LR |
23 | 72 | M | RAEB-1 | VERY-HIGH | 14/4/2014 | COMPLEX | HI + mCR | 11 | 11 | 4 (HI + mCR) | 6 (HI) | 32 | R | ||
24† | 69 | M | RAEB-2 | HIGH | 19/5/2014 | 46, XY | mCR | 6 | 6 | 2 | 3 | 16 | 13 | AML | NR |
25 | 70 | M | RAEB-1 | HIGH | 19/5/2014 | 46, XY, del (7q31) | SD | 7 | 9 | 31 | NR | ||||
26† | 78 | M | RAEB-2 | HIGH | 19/8/2014 | 46, XY | HI + mCR | 17 | 16 | 2 (HI); 2 (mCR) | 14 (HI); 14 (mCR) | 17 | 17 | UNKNOWN | R |